In the last trading session, 1.48 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.76. With the company’s per share price at $38.68 changed hands at -$0.09 or -0.23% during last session, the market valuation stood at $3.34B. CRSP’s last price was a discount, traded about -75.49% off its 52-week high of $67.88. The share price had its 52-week low at $30.04, which suggests the last value was 22.34% up since then.
Analysts gave the CRISPR Therapeutics AG (CRSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.87. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CRSP as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Instantly CRSP was in red as seen at the end of in last trading. With action 2.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -1.73%, with the 5-day performance at 2.90% in the green. However, in the 30-day time frame, CRISPR Therapeutics AG (NASDAQ:CRSP) is 2.41% up.
The consensus price target for the stock as assigned by Wall Street analysts is 65, meaning bulls need an upside of 40.49% from its current market value. According to analyst projections, CRSP’s forecast low is 65 with 65 as the target high. To hit the forecast high, the stock’s price needs a -68.05% plunge from its current level, while the stock would need to soar -68.05% for it to hit the projected low.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
The 2025 estimates are for CRISPR Therapeutics AG earnings to decrease by -22.51%, but the outlook for the next 5-year period is at 7.02% per year.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
ARK INVESTMENT MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.1597% or 7.78 million shares worth $420.12 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Innovation ETF and NEW PERSPECTIVE FUND. With 6.34 shares estimated at $245.29 million under it, the former controlled 7.34% of total outstanding shares. On the other hand, NEW PERSPECTIVE FUND held about 2.96% of the shares, roughly 2.55 shares worth around $98.76 million.
